S&P 500
(0.02%) 5 249.33 points
Dow J
(-0.01%) 39 756 points
Nasdaq
(-0.13%) 16 378 points
Oil
(1.25%) $82.37
Gas
(1.28%) $1.740
Gold
(0.65%) $2 227.10
Silver
(0.12%) $24.78
Platinum
(1.12%) $919.85
USD/EUR
(0.21%) $0.925
USD/NOK
(0.58%) $10.83
USD/GBP
(0.03%) $0.791
USD/RUB
(-0.40%) $92.07

Realtime updates for Inhibikase Therapeutics, [IKT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-03-29)

Expected move: +/- 8.33%

Last Updated28 Mar 2024 @ 09:53

1.52% $ 2.34

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 09:53):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Today's Volume 44 170.00
Average Volume 150 596
Market Cap 14.44M
EPS $-0.860 ( 2023-11-14 )
Next earnings date ( $-0.780 ) 2024-03-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.590
ATR14 $0.0330 (1.43%)
Insider Trading
Date Person Action Amount type
2023-06-30 Berman Dennis N Buy 6 667 Stock Option (right to buy)
2023-06-30 Dion Gisele Buy 6 667 Stock Option (right to buy)
2023-06-30 Grint Paul C Buy 6 667 Stock Option (right to buy)
2023-06-30 Freeman Roy Lester Buy 6 667 Stock Option (right to buy)
2023-03-01 Werner Milton H. Buy 210 000 Stock Option (right to buy)
INSIDER POWER
100.00
Last 59 transactions
Buy: 1 788 769 | Sell: 2 114 883

Inhibikase Therapeutics, Correlation

10 Most Positive Correlations
SVOK0.82
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibikase Therapeutics, Financials

Annual 2022
Revenue: $123 440
Gross Profit: $116 717 (94.55 %)
EPS: $-4.26
Q3 2023
Revenue: $79 569.00
Gross Profit: $73 001.00 (91.75 %)
EPS: $-0.860
Q2 2023
Revenue: $116 410
Gross Profit: $-42 794.00 (-36.76 %)
EPS: $-1.110
Q1 2023
Revenue: $64 521.00
Gross Profit: $59 478.00 (92.18 %)
EPS: $-0.870

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators